Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen
NCT00638807
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Inclusion criteria:
- Diagnosed, active, and symptomatic OA of the knee in a flare state with a functional capacity class of I-III at baseline visit
- Failed adequate trials of both naproxen and ibuprofen (prescription strength) within the past 5 years due to lack of efficacy, tolerability, or both; duration of prescription strength ibuprofen and naproxen must have been a minimum of 2 weeks for each drug at the respective recommended doses if failure was due to lack of efficacy, and for any duration if failure was due to lack of tolerability
Exclusion criteria:
- Inflammatory arthritis or gout/pseudo-gout with acute flare within the past 2 years
(subjects with fibrositis or fibromyalgia will not be excluded)
- Received acetaminophen within 24 hours of the baseline visit
- Use of a mobility assisting device for less than six weeks prior to study screening or
use of a walker
- History of gastrointestinal (GI) perforation, obstruction, or bleeding
- Diagnosed or treated for GI ulcer within 60 days prior to first dose of study
medication
- Received corticosteroids or hyaluronic acid within certain timeframe before study
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Anyang,
- Gwangju,
- Incheon,
- Pusan,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Phoenix, Arizona
- Tucson, Arizona
- Long Beach, California
- Paramount, California
- Tustin, California
- Colorado Springs, Colorado
- Wheat Ridge, Colorado
- DeLand, Florida
- Naples, Florida
- Pembroke Pines, Florida
- Saint Petersburg, Florida
- Woodstock, Georgia
- Overland Park, Kansas
- New Orleans, Louisiana
- Baltimore, Maryland
- Flowood, Mississippi
- Chesterfield, Missouri
- Reno, Nevada
- Albuquerque, New Mexico
- Mason, Ohio
- Beaver, Pennsylvania
- Camp Hill, Pennsylvania
- Jenkintown, Pennsylvania
- Greensboro, South Carolina
- Johnson City, Tennessee
- Murfreesboro, Tennessee
- Nashville, Tennessee
- Austin, Texas
- San Antonio, Texas
- Seattle, Washington
- Birmingham, Alabama
- Buena Park, California
- Denver, Colorado
- Washington, District of Columbia
- Longwood, Florida
- Miami, Florida
- Zephyrhills, Florida
- Boise, Idaho
- Boise, Idaho
- Morton Grove, Illinois
- Wichita, Kansas
- Wichita, Kansas
- Wheaton, Maryland
- Springfield, Missouri
- Bozeman, Montana
- Trenton, New Jersey
- Binghamton, New York
- Brooklyn, New York
- New York, New York
- Cary, North Carolina
- Winston-Salem, North Carolina
- Bismarck, North Dakota
- Eugene, Oregon
- Portland, Oregon
- Duncansville, Pennsylvania
- Johnstown, Pennsylvania
- Warwick, Rhode Island
- Charleston, South Carolina
- New Tazewell, Tennessee
- San Antonio, Texas
- Arlington, Virginia
- Norfolk, Virginia
- Seattle, Washington
- DeLand, Florida
- South Miami, Florida
- Overland Park, Kansas
- Madisonville, Kentucky
- Chesterfield, Missouri
- Creve Coeur, Missouri
- St. Peters, Missouri
- New York, New York
- Cincinnati, Ohio
- Warwick, Rhode Island
- San Antonio, Texas
- Arlington, Virginia
- Clarksburg, West Virginia
- Seoul,
- Seoul,
- Seoul,
- Seoul,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen | |||
Official Title ICMJE | A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen | |||
Brief Summary | To compare the efficacy and safety of celecoxib versus placebo for the treatment of knee osteoarthritis (OA) in patients who were unresponsive to prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 4 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Osteoarthritis, Knee | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 388 | |||
Original Actual Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | July 2004 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria: Inclusion criteria:
Exclusion Criteria: Exclusion criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 40 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00638807 | |||
Other Study ID Numbers ICMJE | A3191082 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | March 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |